T3	outcome-Measure 575 612	pathological complete remission (pCR)
T5	total-participants 698 717	One hundred and two
T6	total-participants 757 759	96
T7	outcome 879 888	pCR rates
T8	iv-bin-percent 894 899	6.8 %
T9	iv-bin-abs 901 902	3
T10	intervention-participants 903 905	45
T11	cv-bin-percent 911 917	17.6 %
T12	cv-bin-abs 919 920	9
T13	control-participants 921 923	51
T14	outcome 1085 1104	event free survival
T17	outcome 1161 1182	disease-free survival
T20	outcome 1390 1416	neutropenia and leucopenia
T15	intervention 23 99	neoadjuvant chemotherapy with docetaxel, anthracycline, and cyclophosphamide
T16	control 107 138	docetaxel plus cyclophosphamide
T1	outcome-Measure 644 650	safety
T2	outcome-Measure 652 674	clinical response rate
T4	outcome-Measure 680 696	survival outcome
T18	outcome 1297 1316	adverse event rates
